Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Neuropharmacology. 2018 Feb 24;133:462–469. doi: 10.1016/j.neuropharm.2018.02.026

Figure 3.

Figure 3

Targeted mutation of AMPA receptor GluA1 Ser831 phosphorylation inhibits NTG-induced migraine-like pain. Compared to the WT mice, the GluA1 S831A mutant mice displayed marked inhibition in NTG-produced photophobia and mechanical hypersensitivity. (A) In the light-aversive behavior test, the time spent in dark compartment following NTG injection significantly decreased in the mutant mice compared to that in the WT mice. (B) In the paw withdrawal threshold test, the mutant mice showed increased paw withdrawal thresholds at 2 h post-NTG compared to those in the WT mice. (C) In the orofacial mechanical hypersensitivity test, the mutant mice showed increased head withdrawal thresholds at 2 h post-NTG compared to those in the WT mice. *P < 0.05 vs baseline, #P < 0.05 vs the WT mice. n = 6 for the WT mice and n = 5 for the mutant mice; two-way ANOVA with the post-hoc Student-Newman-Keuls test was performed. WT, wild-type.